The frequency of NPM1 mutations in childhood acute myeloid leukemia

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Braoudaki, Maria ^a   Papathanassiou, Chrissa ^a   Katsibardi, Katerina ^a   Tourkadoni, Natalia ^a   Karamolegou, Kalliopi ^a   Tzortzatou Stathopoulou, Fotini ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; RAS PROTEIN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL FEATURE; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PROGNOSIS; WILD TYPE; COHORT ANALYSIS; GENE FREQUENCY; GENETICS; INFANT; MUTATION; PRESCHOOL CHILD; SURVIVAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; GENE FREQUENCY; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77958490202     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-41     Document Type: Article

References (23)

1. The incidence and clinical significance of nucleophosmin mutations in childhood AML. P Brown E McIntyre R Rau S Meshinchi N Lacayo G Dahl TA Alonzo M Chang RJ Arceci D Small, Blood 2007 110 979 985 10.1182/blood-2007-02-076604 17440048
2. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia. C Thiede S Koch E Creutzig C Steudel T Illmer M Schaich G Ehninger, Blood 2006 107 4011 4020 10.1182/blood-2005-08-3167 16455956
3. Mutations of NPM1 gene in de novo acute myeloid leukemia: determination of incidence, distribution pattern of two novel mutations in Indian population. F Ahmad S Mandava BR Das, Hematol Oncol 2009 27 90 97 10.1002/hon.883 19365794
4. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. G Cazzaniga MG Dell'Oro C Mecucci E Giarin R Masetti V Rossi F Locatelli MF Martelli G Basso A Pession A Biondi B Falini, Blood 2005 106 1419 1422 10.1182/blood-2005-03-0899 15870172 (Pubitemid 41129610)
5. Clinical Characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. T Suzuki H Kiyoi K Ozeki A Tomita S Yamaji R Suzuki Y Kodera S Miyawaki N Asou K Kuriyama F Yagasaki C Shimazaki H Akiyama M Nishimura T Motoji K Shinagawa A Takeshita R Ueda T Kinoshita N Emi T Naoe, Blood 2005 106 2854 2861 10.1182/blood-2005-04-1733 15994285
6. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. EG Jeong SH Lee NJ Yoo SH Lee, APMIS 2005 115 341 346 10.1111/j.1600-0463.2007. apm-592.x
7. Nucleophosmin mutations in Chinese adults in acute myelogenous leukemia. GR Ruan JL Li YZ Qin LD Li M Xie Y Chang Y Zhang YR Liu B Jiang SS Chen XJ Huang, Ann Hematol 2009 88 159 166 10.1007/s00277-008-0591-8 18726096
8. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. B Falini C Mecucci E Tiacci M Alcalay R Rosati L Pasqualucci R La Starza D Diverio E Colombo A Santucci B Bigerna R Pacini A Pucciarini A Liso M Vignetti P Fazi N Meani V Pettirossi G Saglio F Mandelli F Lo-Coco PG Pelicci MF Martelli GIMEMA Acute Leukemia Working Party, N Engl J Med 2005 352 254 266 10.1056/NEJMoa041974 15659725 (Pubitemid 40110814)
9. Nucleophosmin mutations in de novo acute myeloid leukemia: The age-dependent indices and the stability during disease evolution. WC Chou JL Tang LI Lin M Yao W Tsay CY Chen SJ Wu CF Huang RJ Chiou MH Tseng DT Lin KH Lin YC Chen HF Tien, Cancer Res 2006 66 3310 3316 10.1158/0008-5472.CAN-05-4316 16540685
10. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Y Zhang M Zhang L Yang Z Xiao, Leuk Res 2007 31 109 111 10.1016/j.leukres.2006.03.013 16678898
11. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. S Schnittger C Schoch W Kern C Mecucci C Tschulik MF Martelli T Haferlach W Hiddemann B Falini, Blood 2005 106 3733 3739 10.1182/blood-2005-06-2248 16076867
12. DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. M Syampurnawati E Tatsumi B Ardianto M Takenokuchi Y Nakamachi S Kawano S Kumagai K Saigo T Matsui T Takahashi K Nagai Gunadi H Nishio H Yabe S Kondo Y Hayashi, Leuk Res 2008 32 1141 1143 10.1016/j.leukres.2007.11.017 18180033
13. The role of FLT3 in hematopoietic malignancies. DL Stirewalt JP Radich, Nat Rev Cancer 2003 3 650 665 10.1038/nrc1169 12951584
14. Mutant nucleophosmin (NPM1) predicts favorable diagnosis in younger adults with acure myeloid leukemia and normal cytogenetics: interaction with other gene mutations. K Döhner RF Schlenk M Habdank C Scholl FG Rücker A Corbacioglu L Bullinger S Fröhling H Döhner, Blood 2005 106 3740 3746 10.1182/blood-2005-05-2164 16051734
15. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. M Braoudaki M Karpusas K Katsibardi Ch Papathanassiou K Karamolegou F Tzortzatou-Stathopoulou, Med Oncol 2009 26 460 462 10.1007/s12032-008-9146-z 19085113
16. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of TCTG-tandem duplication in NPM1-exon 12. C Thiede E Creutzig D Reinhardt G Ehninger U Creutzig, Leukemia 2007 21 366 367 10.1038/sj.leu.2404519 17151698
17. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukemia: towards definition of a new leukemia entity. R Rau P Brown, Hematol Oncol 2009 27 171 181 10.1002/hon.904 19569254
18. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. B Linggi C Müller-Tidow L van de Locht M Hu J Nip H Serve WE Berdel B van der Reijden DE Quelle JD Rowley J Cleveland JH Jansen PP Pandolfi SW Hiebert, Nat Med 2002 8 743 750 10.1038/nm726 12091906
19. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. SC Raimondi MN Chang Y Ravindranath FG Behm MV Gresik CP Steuber HJ Weinstein AJ Carroll, Blood 1999 94 3707 3716 10572083
20. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. J Pedersen-Bjergaard MK Andersen DH Christiansen C Nerlov, Blood 2002 99 1909 1912 10.1182/blood.V99.6.1909 11877259 (Pubitemid 34525468)
21. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. M Shiseki Y Kitagawa YH Wang K Yoshinaga T Kondo H Kuroiwa M Okada N Mori T Motoji, Leuk Lymphoma 2007 48 2141 2144 10.1080/10428190701615900 17990177
22. Nucleophosmin mutation in the Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistance and prognostic impact of NPM1/FLT3 mutations. C Boonthimat W Thongnoppakhun CU Auewarakul, Hematologica 2008 93 1565 1569 10.3324/haematol.12937
23. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other abnormalities and previously established gene expression signatures and their favorable prognostic significance. RG Verhaak CS Goudswaard W van Putten MA Bijl MA Sanders,, et al. Blood 2005 106 3747 3754 10.1182/blood-2005-05-2168 16109776